Medical device startup InnerOptic Technology has secured as much as $370,000 in financing, the company said Wednesday.

CatoBioVentures has agreed to invest as much as $270,000 and an unidentified angel investor added another $100,000.

And InnerOptic isn’t finished. With a new chief executive officer onboard, InnerOptic is seeking to raise several million dollars early next year.

The company is developing technology licensed from the University of North Carolina that provides surgeons with a 3-D view of a patient’s body during minimally invasive surgery.

“Attracting private investment demonstrates a major vote of confidence in InnerOptic’s strategy. This funding will allow us to achieve several important product development milestones in the next few months,” said CEO Brian Heaney.

The funds will be used to further develop its InVision System for use in laparoscope procedures.

"Cato BioVentures looks forward to a long and successful relationship with InnerOptic and is excited to assist the company in achieving important milestones in the neat future,” said Joel Eisner, an associate principal at Cato BioVentures.

Heaney, a veteran with experience at Apple and General Electric, joined InnerOptic last month.

The firm, which company founder Kurtis Keller launched in 2003, has received a variety of federal grants and some angel funding.

InnerOptic wants to raise $4.3 million by March of next year in order to further refine its products and to add staff.

InVision is designed to help surgeons use ultrasound more easily during minimally invasive procedures. InnerOptic hopes to win final Food and Drug Administration approval for InVision next year.

The second device, called the Laparoscope, provides real-time imagery of the area where minimally invasive surgery of the abdomen, or laparoscopic surgery, is being performed. InnerOptic is developing patented technology that will enable surgeons to “see” the procedure they are performing through a head-mounted display rather than having to watch a TV monitor.

The company is also developing cancer-detection capability.